Last updated: April 25, 2026
What suppliers provide cefoxitin sodium (API) and related sterile or finished offerings?
Cefoxitin sodium is a widely used injectable cephalosporin. In practice, market supply splits into (1) API manufacturers (cefoxitin sodium) and (2) finished-dose sterile injectables (often where the label lists “cefoxitin sodium” as the drug substance). Supplier visibility depends on whether you are buying API or finished product.
High-confidence supplier set based on public market footprints and typical procurement pathways includes the following manufacturer and distributor channels that have historically participated in cefoxitin sodium supply for global and US markets:
API and injectable manufacturing sources (typical market participants)
| Supplier / company |
Supply role in market |
Evidence basis used here |
| Jubilant Pharmova |
Injectable/cephalosporin manufacturing (API and/or finished-dose pathways) |
Public manufacturing footprint for sterile injectables and cephalosporin families |
| Sandoz (Novartis) |
Finished-dose sterile supply in many legacy antibiotics markets |
Established branded and generic sterile supply for beta-lactams historically |
| Fresenius Kabi |
Finished-dose antibiotics supply channel |
Established sterile injection manufacturing footprint |
| Hospira (Pfizer legacy, where applicable) |
Finished-dose supply channel (legacy role) |
Established sterile antibiotic supply chain for US/EU markets |
| Mylan / Viatris |
Finished-dose generic supply channel |
Generic injectable portfolio presence for cephalosporins |
| Teva |
Finished-dose generic supply channel |
Injectable beta-lactam portfolio presence |
| Hikma |
Finished-dose generic supply channel |
Injectable portfolio presence and sourcing capacity |
Important procurement distinction: Many firms that “supply cefoxitin sodium” in distribution are finished-dose suppliers, while API supply can come from a smaller set of chemical and antibiotic fermentation manufacturers under contract. Without a product-specific buyer document (purchase order spec, DMF/ASMF holder, or labeling history for a given NDC), the strongest actionable answer is to anchor sourcing to the finished-dose product label history for the relevant geography and then trace to the API manufacturing site via DMF/ASMF relationships.
Which finished-dose product labels drive the most reliable supplier identification?
For cefoxitin sodium, the fastest way to name suppliers with audit-ready traceability is to start from the NDC-labeled product(s) that are active in the target market, then identify the manufacturer listed on the label and the labeler (commercial distributor). Those entities are the de facto suppliers to wholesalers and hospital group purchasing organizations.
Procurement-grade sourcing map
| What you buy |
The supplier you can contract with |
What you can usually verify quickly |
| Cefoxitin sodium API |
API manufacturer or contract API packager |
ASMF/DMF holder name and manufacturing site (when registered) |
| Cefoxitin sodium sterile injection |
Manufacturer or labeler of finished dosage |
Labeler/manufacturer name on cartons and NDC listing |
| Cefoxitin sodium procurement via distributors |
Hospital/wholesale distributor or pharma distributor |
Distribution records tied to NDC/manufacturer |
How is cefoxitin sodium typically produced and what does that imply for supplier selection?
Cefoxitin sodium is a semi-synthetic cephalosporin. Commercial supply is usually tied to one or both of these steps:
- Industrial cephalosporin fermentation and isolation (upstream antibiotic core)
- Semi-synthetic conversion and sodium salt formation (drug substance finishing)
That structure drives supplier selection toward firms with:
- Cephalosporin antibiotic manufacturing capability (fermentation and beta-lactam handling)
- Sterile injectable capability if supplying finished dosing
- Regulatory registrations for the geography (US FDA listing if targeting US)
What supplier types should you shortlist for R&D or procurement?
Category 1: API manufacturers
Shortlist only firms with explicit antibiotic API manufacturing history and regulatory filings (commonly DMF/ASMF-linked). The key is that they can supply:
- Cefoxitin sodium at controlled specs (particle size, assay, impurities)
- Consistent batch-to-batch profile aligned with your qualification plan
Category 2: Finished-dose sterile manufacturers
Shortlist firms that already sell cefoxitin sodium sterile injections (or close beta-lactam injectables) in your region. They provide:
- Regulatory-ready packaging and sterility assurance
- Defined NDC and lot traceability for downstream audit
Category 3: Contract manufacturing organizations (CMOs)
If you cannot find direct API or finished-dose supply, CMOs are frequently the practical route. Their value is throughput and validated sterile processes, but the supplier name you contract with is the CMO operator, not the DMF holder.
What are the practical supplier criteria for cefoxitin sodium?
Procurement and R&D qualification for cefoxitin sodium typically hinges on:
Drug substance criteria (API)
- Assay/purity within validated spec ranges
- Impurity control for beta-lactam related degradation and residuals
- Salt form consistency (cefoxitin sodium)
- Stability data supporting your storage and reconstitution conditions
Finished dose criteria (sterile injection)
- Sterility assurance and container closure integrity
- Endotoxin limits and microbial limits where required
- Strength confirmation (mg/mL) and fill volume uniformity
- Labeling and lot traceability through NDC/labeler
Supplier due diligence checklist (what to validate before awarding a supply contract)
| Due diligence item |
Why it matters for cefoxitin sodium supply |
| Regulatory status in your target market |
Prevents late-stage supply disruption due to listing gaps |
| Manufacturing site history for beta-lactams |
Reduces risk of batch inconsistency |
| Batch release and COA availability |
Confirms specs, impurities, and stability alignment |
| Sterile process track record (if finished dose) |
Ensures sterility and container-closure reliability |
| Supply continuity and allocation policy |
Cefoxitin sodium can experience periodic shortages in legacy antibiotics markets |
Key Takeaways
- Cefoxitin sodium supply is best sourced through finished-dose labelers/manufacturers for fast, auditable supplier identification, then traced to API manufacturing via filings where needed.
- Supplier shortlists should focus on cephalosporin beta-lactam capability, regulatory listing in the target market, and batch traceability.
- Contracting should be category-based: API manufacturers for drug substance, sterile injectable manufacturers for finished product, with CMOs as the fallback when direct supply is constrained.
FAQs
1) What is the difference between suppliers of cefoxitin sodium API and those of cefoxitin sodium sterile injection?
API suppliers manufacture the drug substance (cefoxitin sodium). Sterile injection suppliers manufacture and package the final sterile dosage product under an NDC/labeler.
2) What’s the fastest way to identify a credible supplier for procurement?
Start with active NDC-labeled cefoxitin sodium products in the target geography and identify the labeler/manufacturer listed on the packaging, then trace upstream through DMF/ASMF relationships where required.
3) Which supplier category matters most for R&D comparability studies?
API supplier identity and manufacturing site matter most for comparability of the drug substance. Finished-dose suppliers matter more for container, sterility, and final potency delivery.
4) Why do antibiotic shortages affect cefoxitin sodium sourcing?
Cefoxitin sodium is a legacy injectable that depends on specific upstream antibiotic intermediates and sterile capacity; disruptions upstream or in sterile batch release can trigger allocations.
5) What specs should you require first for qualification?
For API: assay/purity and impurity profile. For finished dose: strength confirmation, sterility/endotoxin limits, and container closure integrity.
References
[1] FDA. Drugs@FDA: Drug Products (Cefoxitin Sodium-associated listings). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] DailyMed. Cefoxitin Sodium injection labels and manufacturer/labeler listings. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
[3] EMA. European public assessment data for cephalosporin-class products and manufacturing authorizations (where applicable). European Medicines Agency. https://www.ema.europa.eu/
